Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicinal preparation for treating osteoarthritis

A technology for osteoarthritis and pharmaceutical preparations, applied in the field of orally disintegrating tablets, can solve the problems of slow onset of action, achieve the effects of taking convenience, reducing dosage, and improving symptoms

Inactive Publication Date: 2009-03-04
NAT INST OF PHARMA R & D CO LTD
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] The latest test results show that dextrobuprofen and glucosamine have definite curative effects and high safety, but when used alone, dextrobuprofen can only relieve symptoms, while glucosamine is slow to take effect, and both have defects. When Iprofen and glucosamine are used in combination, it has a significant synergistic effect on analgesia, while the combination of glucosamine and other analgesic drugs such as acetaminophen, diclofenac, indomethacin, piroxicam, naproxen, etc. Only additivity, aggravation and even no effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] prescription one

[0036] Dexibuprofen 100 parts

[0037] Glucosamine 300 parts

[0038] 20 parts of crospovidone

[0039] Microcrystalline cellulose 50 parts

[0040] 3 parts stearic acid

[0041] 1 part cyclamate

[0042] Proper amount of hydroxypropyl methylcellulose

[0043] Preparation: Weigh each component, pass through a 100-mesh sieve, stir and mix evenly, add magnesium stearate, and press the powder directly into tablets.

[0044] The disintegration time limit is 20 seconds.

Embodiment 2

[0046] Weigh each component, pass through a 100-mesh sieve, stir and mix evenly, add micronized silica gel, and directly compress the powder into tablets.

[0047] Dexibuprofen 100 parts

[0048] Glucosamine 300 parts

[0049] 20 parts of crospovidone

[0050] Sodium carboxymethyl cellulose 20 parts

[0051] Microcrystalline cellulose 50 parts

[0052] 2 parts magnesium stearate

[0053] Stevioside 2 parts

[0054] Proper amount of hydroxypropyl methylcellulose

[0055] Preparation: Weigh each component, pass through a 100-mesh sieve, stir and mix evenly, add micronized silica gel, and directly compress the powder into tablets.

[0056] The disintegration time limit is 30 seconds.

Embodiment 3

[0058] Dexibuprofen 100 parts

[0059] Glucosamine 300 parts

[0060] Sodium carboxymethyl cellulose 30 parts

[0061] Lactose 60 parts

[0062] Macrogol 4000 2 parts

[0063] Stevioside 0.5 parts

[0064] Appropriate amount of water

[0065] Preparation: Weigh each component, pass through a 100-mesh sieve, stir and mix evenly, add magnesium stearate, and press the powder directly into tablets.

[0066] The disintegration time limit is 25 seconds.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical preparation for the treatment of osteoarthritis. The active ingredients of the preparation are composed of cextrogire brufen and glucosamine or the medicinal composite salt according to the proportion of 1: 3. The combination is prepared into the pharmaceutical preparation which has stable quality and convenient administration through the preparation forming mode, and the pharmaceutical preparation comprises orally disintegrating tablets.

Description

technical field [0001] The invention relates to a pharmaceutical preparation for treating osteoarthritis. The active ingredient of the preparation is a composition composed of dexibuprofen and glucosamine or a medicinal salt thereof in a ratio of 1:3. , prepared into pharmaceutical dosage forms with stable quality and easy to take, including orally disintegrating tablets. technical background [0002] Osteoarthritis (OA), also known as osteoarthritis, degenerative joint disease, senile arthritis, proliferative arthritis, hypertrophic arthritis, is divided into primary arthritis and secondary arthritis. Osteoarthritis is characterized by pain, inflammation, stiffness, swelling, deformity, and dysfunction in the joints of the hands, wrists, ankles, knees, hips, shoulders, and spine. The articular cartilage of the human body inevitably degenerates and wears out with age. The degeneration of cartilage begins in the late 20s. Most people over the age of 50 can show the performan...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7008A61K9/20A61K47/38A61P19/02A61K31/192
Inventor 孙从新曾小伟郑少辉
Owner NAT INST OF PHARMA R & D CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com